Connect Biopharma Holdings Limited Ordinary Shares CNTB
$2.17
-5.65%
at last close
Market Cap$136.63 million
P/E Ratio—
Div Yield—
Volume277.6K
52-Week Range
$0.70$3.82
Key Stats
- Today's Range
- $2.13 – $2.43
- 50-Day Range
- $2.13 – $3.82
- 52-Week Range
- $0.70 – $3.82
- Volume
- 278K shs
- Average Volume
- 183K shs
- Market Cap
- $136.63 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 3.21
- Price / Sales
- 586.40
Short Interest
- Short Interest
- 1.23%
- Days to Cover
- 1.64
Financials (TTM)
- Revenue
- $233,000
- Net Income
- $-64,606,000
- Net Margin
- -27727.90%
- Return on Equity
- -151.58%
- Debt-to-Equity
- —
About Connect Biopharma Holdings Limited Ordinary Shares
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Related Stocks
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.